DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

9 API Suppliers, 2 NDC API, 1 VMF, 9 Listed Suppliers

9 API Suppliers
2 NDC API
1 VMF
9 Listed Suppliers

INTERMEDIATES

4 Intermediates Suppliers

4 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

13 FDF Dossiers, 9 Canada, 4 Listed Dossiers

13 FDF Dossiers
9 Canada
4 Listed Dossiers

DIGITAL CONTENT

1 DATA COMPILATION #PharmaFlow, 3 NEWS #PharmaBuzz

media
1 DATA COMPILATION #PharmaFlow
3 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

6 Annual Reports

globalSalesInformation
6 Annual Reports

MARKET PLACE

2 APIs

marketPlace
2 APIs

PATENTS & EXCLUSIVITIES

4 Health Canada Patents

patents
4 Health Canada Patents

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

4INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

0 DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

5,898

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 1093861-60-9, Afoxolaner [usan], 02l07h6d0u, Afoxolaner (usan), 4-[5-[3-chloro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4h-1,2-oxazol-3-yl]-n-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]naphthalene-1-carboxamide, 4-(5-(3-chloro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-n-(2-oxo-2-((2,2,2-trifluoroethyl)amino)ethyl)-1-naphthamide

Molecular Formula

C₂₆H₁₇ClF₉N₃O₃

Molecular Weight

625.9 g/mol

InChI Key

OXDDDHGGRFRLEE-UHFFFAOYSA-N

FDA UNII

02L07H6D0U

1 2D Structure

Afoxolaner

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

4-[5-[3-chloro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-1,2-oxazol-3-yl]-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]naphthalene-1-carboxamide

2.1.2 InChI

InChI=1S/C26H17ClF9N3O3/c27-15-8-13(7-14(9-15)25(31,32)33)23(26(34,35)36)10-20(39-42-23)18-5-6-19(17-4-2-1-3-16(17)18)22(41)37-11-21(40)38-12-24(28,29)30/h1-9H,10-12H2,(H,37,41)(H,38,40)

2.1.3 InChI Key

OXDDDHGGRFRLEE-UHFFFAOYSA-N

2.1.4 Canonical SMILES

C1C(=NOC1(C2=CC(=CC(=C2)Cl)C(F)(F)F)C(F)(F)F)C3=CC=C(C4=CC=CC=C43)C(=O)NCC(=O)NCC(F)(F)F

2.2 Other Identifiers

2.2.1 UNII

02L07H6D0U

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 4-(5-(3-chloro-5-(trifluoromethyl)-phenyl)-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl)-n-(2- Oxo-2-((2,2,2-trifluoroethyl)amino)ethyl-1-naphthalenecarboxamide

2.3.2 Depositor-Supplied Synonyms

1. 1093861-60-9

2. Afoxolaner [usan]

3. 02l07h6d0u

4. Afoxolaner (usan)

5. 4-[5-[3-chloro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4h-1,2-oxazol-3-yl]-n-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]naphthalene-1-carboxamide

6. 4-(5-(3-chloro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-n-(2-oxo-2-((2,2,2-trifluoroethyl)amino)ethyl)-1-naphthamide

7. 4-[5-[3-chloro-5-(trifluoromethyl)phenyl]-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-n-[2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl]-1-naphthalenecarboxamide

8. Afoxolaner [usan:inn]

9. Unii-02l07h6d0u

10. Nexgard

11. Afoxolaner [mi]

12. Afoxolaner [inn]

13. C26h17clf9n3o3

14. Schembl119580

15. Afoxolaner [green Book]

16. Chembl2219412

17. Dtxsid50148921

18. Bcp21108

19. Ex-a3267

20. Afoxolaner [ema Epar Veterinary]

21. Hy-16974

22. Nexgard Spectra Conponent Afoxolaner

23. Cs-0013215

24. Afoxolaner Conponent Of Nexgard Spectra

25. J3.498.573a

26. D10361

27. Q21051346

28. 1-naphthalenecarboxamide, 4-(5-(3-chloro-5-(trifluoromethyl)phenyl)-4,5-dihydro-5- (trifluoromethyl)-3-isoxazolyl)-n-(2-oxo-2-((2,2,2-trifluoroethyl)amino)ethyl)-

29. 1-naphthalenecarboxamide, 4-(5-(3-chloro-5-(trifluoromethyl)phenyl)-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl)-n-(2-oxo-2-((2,2,2-trifluoroethyl)amino)ethyl)-

30. 4-(5-(3-chloro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl(-n- (2-oxo-2-((2,2,2-trifluoroethyl)amino)ethyl(naphthalene-1-carboxamide

31. 4-(5-(3-chloro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-n-(2-oxo-2-((2,2,2-trifluoroethyl)amino)ethyl)naphthalene-1-carboxamide

32. 4-[(5r)-5-[3-chloro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4h-1,2-oxazol-3-yl]-n-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]naphthalene-1-carboxamide

2.4 Create Date

2009-02-23

3 Chemical and Physical Properties

Molecular Formula	C₂₆H₁₇ClF₉N₃O₃
Molecular Weight	625.9 g/mol
XLogP3	6.7
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	13
Rotatable Bond Count	6
Exact Mass	625.0814726 g/mol
Monoisotopic Mass	625.0814726 g/mol
Topological Polar Surface Area	79.8 Å²
Heavy Atom Count	42
Formal Charge	0
Complexity	1040
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	1
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

Treatment of flea infestation in dogs (Ctenocephalides felis and C. canis) for at least 5 weeks. The product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).

Treatment of tick infestation in dogs (Dermacentor reticulatus, Ixodes ricinus, Ixodes hexagonus, Rhipicephalus sanguineus). One treatment kills ticks for up to one month.

Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.

Treatment of demodicosis (caused by Demodex canis).

Treatment of sarcoptic mange (caused by Sarcoptes scabiei var. canis).

5 Pharmacology and Biochemistry

5.1 ATC Code

QP53BE01

API SUPPLIERS

01

Rochem International Inc

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Suppliers Night Expo

Attending

Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

Contact Supplier

U.S.A

Virtual Booth

Digital Content

USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT

02

ChemWerth Inc

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

CPhI WW Frankfurt

Booth #12.1F43

ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

Contact Supplier

U.S.A

Virtual Booth

Digital Content

USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT

03

Suanfarma

Spain

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

CPHI Middle east

Booth #1.G23

Suanfarma, at the Core of a Better Life.

Contact Supplier

Spain

Virtual Booth

Digital Content

USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT

04

Shandong Chenghui Shuangda Pharmac...

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

CPhI China

Attending

Shuangda Pharmaceutical has a world-class first-class production line, having GMP, FDA and other regulatory certifications.

Contact Supplier

China

Virtual Booth

Digital Content

USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT

Shandong Chenghui Shuangda Pharmaceutical

05

Jinan Tantu Chemicals

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Medlab Asia & Asia Health

Not Confirmed

Jinan Tantu Chemicals offers customized R&D services & production of small molecule APIs & pharmaceutical intermediates.

Contact Supplier

China

Virtual Booth

Digital Content

USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT

06

Supriya Lifescience

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Medlab Asia & Asia Health

Not Confirmed

Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.

Contact Supplier

India

Virtual Booth

Digital Content

USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT

07

Alivira Animal Health

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Medlab Asia & Asia Health

Not Confirmed

08

Sichuan Qingmu Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Medlab Asia & Asia Health

Not Confirmed

09

Zenfold Sustainable Technologies

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Medlab Asia & Asia Health

Not Confirmed

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

VMF

01

Wisdom Pharmaceutical Co Ltd

China

AES 2024

Not Confirmed

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

INTERMEDIATES SUPPLIERS

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Canada

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Dossiers

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

NEWS #PharmaBuzz

Global Sales Information

Do you need Business Intel? Ask us

Annual Reports

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Market Place

Do you need sourcing support? Ask us

APIs

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

Health Canada Patents

01

Boehringer lngelheim Animal Health Canada ...

Afoxolaner

AES 2024

Not Confirmed

02

Boehringer lngelheim Animal Health Canada ...

Afoxolaner

AES 2024

Not Confirmed

03

Boehringer lngelheim Animal Health Canada ...

Afoxolaner

AES 2024

Not Confirmed

04

Boehringer lngelheim Animal Health Canada ...

Afoxolaner

AES 2024

Not Confirmed

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Find Afoxolaner manufacturers, exporters & distributors on PharmaCompass

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

9 API Suppliers

2 NDC API

1 VMF

9 Listed Suppliers

INTERMEDIATES

4 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

13 FDF Dossiers

9 Canada

4 Listed Dossiers

DIGITAL CONTENT

1 DATA COMPILATION #PharmaFlow

3 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

6 Annual Reports

MARKET PLACE

2 APIs

PATENTS & EXCLUSIVITIES

4 Health Canada Patents

ACTIVE PHARMA INGREDIENTS

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

FINISHED DOSAGE FORMULATIONS

0 DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

PATENTS & EXCLUSIVITIES

DIGITAL CONTENT

GLOBAL SALES INFORMATION

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

01

02

03

04

05

06

07

08

09

01

01

01

02

03

04

What are you looking for?